Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504728 | 0.89 | SMN1; SMN2 (0.56) | CYP11B1CYP11B2LMNAF10MAPT | |
| SCHEMBL1504566 | 0.88 | HDAC1 (0.49) | LMNAKDM4EMAPTALDH1A1NPC1 | |
| SCHEMBL1504699 | 0.83 | HDAC1 (0.46) | F10KDM4EMAPTALDH1A1NPC1 | |
| SCHEMBL1504668 | 0.81 | HDAC1 (0.42) | LMNAF10KDM4EMAPTALDH1A1 | |
| SCHEMBL1504703 | 0.81 | MAPK14 (0.47) | KDM4EMAPTALDH1A1MAPK14TP53 | |
| SCHEMBL1504789 | 0.80 | MAPK14 (0.47) | MAPK14CYP1A2KMT2A | |
| SCHEMBL1504540 | 0.80 | NPC1 (0.52) | CYP11B1CYP11B2LMNAF10KDM4E | |
| SCHEMBL1504764 | 0.80 | HDAC1 (0.39) | F10KDM4EMAPTALDH1A1NPC1 | |
| SCHEMBL1504662 | 0.80 | MAPK14 (0.47) | KDM4EALDH1A1SMN1; SMN2MAPK14CYP2C9 | |
| SCHEMBL1504645 | 0.79 | NPC1 (0.47) | MAPK7NPC1SMN1; SMN2MAPK14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | CYP11B1 188/4885CYP11B2 288/4885LMNA 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.